Follow
Zara Ioannides
Zara Ioannides
Verified email at uq.edu.au
Title
Cited by
Cited by
Year
Hypermetabolism in ALS is associated with greater functional decline and shorter survival
FJ Steyn, ZA Ioannides, RPA Van Eijk, S Heggie, KA Thorpe, A Ceslis, ...
Journal of Neurology, Neurosurgery & Psychiatry 89 (10), 1016-1023, 2018
2042018
Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
MP Pender, PA Csurhes, C Smith, NL Douglas, MA Neller, KK Matthews, ...
JCI insight 3 (22), 2018
1412018
Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression
ZA Ioannides, ST Ngo, RD Henderson, PA McCombe, FJ Steyn
Neurodegenerative Diseases 16 (5-6), 382-397, 2016
522016
Anthropometric measures are not accurate predictors of fat mass in ALS
ZA Ioannides, FJ Steyn, RD Henderson, PA Mccombe, ST Ngo
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18 (7-8), 486-491, 2017
262017
Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein–Barr virus-specific T cell therapy
ZA Ioannides, PA Csurhes, KM Thompson, MP Pender
Frontiers in Neurology 12, 652811, 2021
212021
Susac syndrome and multifocal motor neuropathy first manifesting in pregnancy
ZA Ioannides, C Airey, N Fagermo, S Blum, PA McCombe, RJ Henderson
Australian and New Zealand Journal of Obstetrics and Gynaecology 53 (3), 314-317, 2013
212013
Neuromuscular disorders in pregnancy
C Edmundson, AC Guidon
Seminars in Neurology 37 (06), 643-652, 2017
152017
Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis
ZA Ioannides, PA Csurhes, A Swayne, P Foubert, BT Aftab, MP Pender
Multiple Sclerosis Journal–Experimental, Translational and Clinical 7 (2 …, 2021
102021
When does ALS start? A novel SOD-1 p. Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms
ZA Ioannides, RD Henderson, T Robertson, M Davis, PA McCombe
Journal of Neurology, Neurosurgery & Psychiatry 87 (9), 1031-1032, 2016
92016
Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free mass
ZA Ioannides, FJ Steyn, JD Mi, RD Henderson, PA McCombe, ST Ngo
Cogent Medicine 4 (1), 1343000, 2017
82017
Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus …
A Bar-Or, MP Pender, SJ Hodgkinson, S Broadley, JW Lindsey, ...
MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 72-72, 2022
7*2022
Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis
MP Pender, PA Csurhes, C Smith, NL Douglas, MA Neller, L Beagley, ...
Multiple Sclerosis Journal 23, 401-401, 2017
42017
Long-term disability improvement during EBV-targeted T-cell immunotherapy ATA188 is related to brain volume change and normalised magnetisation transfer ratio in T2 lesions
S Noteboom, D Arnold, A Bar-Or, M Pender, S Hodgkinson, S Broadley, ...
Multiple Sclerosis Journal 28 (3_ SUPPL), 1005-1006, 2022
32022
The utility of FDG-PET in complex neurological conditions.
ZA Ioannides, P Thomas, D Langguth, P Kubler, RD Henderson
Internal Medicine Journal 47 (12), 1460-1462, 2017
22017
Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of …
M Pender, P Csurhes, C Smith, N Douglas, M Neller, L Beagley, S Rehan, ...
Neurology 89 (8), E103-E103, 2017
22017
Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherpy for progressive forms of multiple sclerosis
MP Pender, SJ Hodgkinson, S Broadley, J Lindsey, ZA Ioannides, ...
Mult Scler 26, S3228, 2020
12020
Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with …
M Pender, S Hodgkinson, S Broadley, J Lindsey, Z Ioannides, D Munson, ...
Multiple Sclerosis Journal 25, 931-932, 2019
12019
Hypermetabolism in motor neurone disease is associated with a greater functional decline but not weight loss
ZA Ioannides, ST Ngo, RD Henderson, PA McCombe, FJ Steyn
Journal of Neurology, Neurosurgery & Psychiatry 88 (5), e1-e1, 2017
12017
Preliminary phase 1 safety of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus (EBV)-targeted T-cell immunotherapy for patients with …
MP Pender, S Hodgkinson, S Broadley, JW Lindsey, ZA Ioannides, ...
European Journal of Neurology 26, 683-683, 2019
2019
Energy metabolism in amyotrophic lateral sclerosis: Assessment of body composition and energy expenditure
ZA Ioannides
2017
The system can't perform the operation now. Try again later.
Articles 1–20